1. Evolving Standards in HER2-Targeted Adjuvant Therapy for Breast Cancer

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Overview

4. Overview (cont)

5. Neratinib ExteNet Trial

6. Interim Analysis of 5-Year Follow-Up Data From ExteNet

7. APHINITY Trial

8. APHINITY Trial (cont)

9. Results of Subgroup Analysis of Invasive DFS at 4 Years

10. Safety Profile

11. Interpreting the Pertuzumab Findings

12. ALTTO Trial

13. Trials Evaluating Ado-Trastuzumab Emtansine (T-DM1) in Adjuvant Setting

14. Conclusions and Unanswered Questions

15. Abbreviations